Medical Editor: John P. Cunha, DO, FACOEP
Humulin 70-30 (70% human insulin isophane suspension and 30% human insulin) is a man-made form of a hormone that is produced in the body used to treat diabetes. The most common side effect of Humulin 70-30 is low blood sugar (hypoglycemia). Symptoms of low blood sugar may include headache, nausea, hunger, confusion, drowsiness, weakness, dizziness, blurred vision, fast heartbeat, sweating, tremor, trouble concentrating, confusion, or seizure (convulsions). Other side effects of Humulin 70-30 include:
- injection site reactions (e.g., pain, redness, irritation),
- skin thickening or pits at the injection site (lipodystrophy),
- weight gain, and
- swelling of your hands and feet.
Each patient's diabetes is different, and the injection schedule and use of Humulin 70-30 is individualized. A doctor determines which insulin to use, how much, and when and how often to inject it. Humulin 70-30 may interact with albuterol, clonidine, reserpine, guanethidine, or beta-blockers. Tell your doctor all medications you are taking. Tell your doctor if you are pregnant before using Humulin 70-30. If you are planning pregnancy, discuss a plan for managing your blood sugars with your doctor before you become pregnant. Your doctor may switch the type of insulin you use during pregnancy. This medication does not pass into breast milk. Consult your doctor before breastfeeding. Insulin needs may change while breastfeeding.
Our Humulin 70-30 (70% human insulin isophane suspension and 30% human insulin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Get emergency medical help if you have any of these signs of insulin allergy: itching skin rash over the entire body, wheezing, trouble breathing, fast heart rate, sweating, or feeling like you might pass out.
Hypoglycemia, or low blood sugar, is the most common side effect of insulin isophane and insulin regular. Symptoms of low blood sugar may include headache, nausea, hunger, confusion, drowsiness, weakness, dizziness, blurred vision, fast heartbeat, sweating, tremor, trouble concentrating, confusion, or seizure (convulsions). Watch for signs of low blood sugar. Carry a piece of non-dietetic hard candy or glucose tablets with you in case you have low blood sugar.
Tell your doctor if you have itching, swelling, redness, or thickening of the skin where you inject insulin isophane and insulin regular.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Humulin 70-30 (Insulin (Human Recombinant))
The following adverse reactions are discussed elsewhere in the labeling:
The following additional adverse reactions have been identified during post-approval use of HUMULIN 70/30. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.
Some patients taking HUMULIN 70/30 have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported [see WARNINGS AND PRECAUTIONS].
Some patients taking HUMULIN 70/30 have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Administration of insulin subcutaneously, including HUMULIN 70/30, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND ADMINISTRATION] in some patients.
Weight gain has occurred with some insulin therapies including HUMULIN 70/30 and has been attributed to the anabolic effects of insulin and the decrease in glycosuria.
Development of antibodies that react with human insulin have been observed with all insulin, including HUMULIN 70/30.
Read the entire FDA prescribing information for Humulin 70-30 (Insulin (Human Recombinant))
© Humulin 70-30 Patient Information is supplied by Cerner Multum, Inc. and Humulin 70-30 Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.